In a significant development, Eli Lilly's experimental pill, muvalaplin, has shown remarkable efficacy in reducing an inherited form of high cholesterol in a mid-stage clinical trial. Presented at the American Heart Association meeting in Chicago, the trial data revealed that muvalaplin led to a substantial decrease in lipoprotein(a) levels, a risk factor for heart disease that affects a substantial portion of the global population.
Unlike commonly known cholesterol types like LDL, high levels of Lp(a) have no approved treatments available and often go undetected in individuals. Elevated Lp(a) significantly raises the risk of cardiovascular issues such as heart attacks, stroke, aortic valve stenosis, and peripheral artery disease, particularly affecting individuals of African and South Asian descent.
The trial, which included 233 adults with high Lp(a) levels, tested three daily doses of muvalaplin - 10, 60, and 240 milligrams - against a placebo. The results showed a significant reduction in Lp(a) levels, with the highest dose of 240 mg leading to an 86% decrease as measured by a specific blood test developed by the company.
Ruth Gimeno, Lilly's group vice president for diabetes and metabolic research, expressed enthusiasm about the results and highlighted the need for further large-scale trials to confirm the drug's ability to reduce cardiovascular events. Although discussions with regulators are pending, the promising outcomes of muvalaplin suggest a potential breakthrough in addressing high Lp(a) levels and associated cardiovascular risks.